Key facts
- This page summarizes Michael Patrick Miller's Form 4 filing for PUMA BIOTECHNOLOGY, INC. (PBYI).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 15 Jun 2023, 20:28.
Michael Patrick Miller - 13 Jun 2023 Form 4 Insider Report for PUMA BIOTECHNOLOGY, INC. (PBYI)
- Reporting relationship
- Director
- Issuer ticker
- PBYI
- Reported as of
- 13 Jun 2023
- Net transaction value
- -$46,630
- SEC form
- 4
- Accepted by SEC
- 15 Jun 2023, 20:28:13 UTC
- Prior SEC filing
- 10 Aug 2022
- Next SEC filing
- 28 Jun 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Gordon Esplin as attorney-in-fact for Michael P. Miller
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Michael Patrick Miller filed Form 4 for PUMA BIOTECHNOLOGY, INC. (PBYI) on 15 Jun 2023.
Change
- Previous filing in this sequence was filed on 10 Aug 2022.
- Current net transaction value: -$46,630.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
PBYI
transaction
Common Stock
Sale
- Transaction value
- $46,630
- Shares
- -13,500
- Change %
- -25%
- Price
- $3.45
- Shares after
- 41,358
- Date
- 13 Jun 2023
- Ownership
- Direct
- Footnotes
- F1, F2
PBYI
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +27,000
- Change %
- +65%
- Price
- $0.000000
- Shares after
- 68,358
- Date
- 13 Jun 2023
- Ownership
- Direct
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 3 footnotes
Footnote F1
Adoption date of referenced 10b5-1(c) sell to cover program is: 12-14-2022.
Footnote F2
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.43 to $3.47, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
Footnote F3
Represents Restricted Stock Units which vest in full on the earlier of the one-year anniversary of the date of grant and the date of the annual shareholder meeting following the date of grant, subject to the Reporting Person's continued service with the Issuer.